Latest Breaking News On - Holger eltzschig - Page 1 : comparemela.com

Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth). Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of HIF, which can lead to improved oxygen delivery to tissues. Stabilization of HIF can help to dampen alveolar inflammation, a key problem that patients with COVID-19-associated lung disease are facing when they develop ARDS. The drug is investigational in the U.S. but has been

Katherineg mcgovernHolger eltzschigEmily hendersonBen bobrowUs department of defenseHarris healthPeer reviewed medical research programKathrineg mcgovern distinguished university chairTexas medical centerDepartment of anesthesiologyTranslational sciencesAkebia therapeutics incEmergency medicine at mcgovern medical schoolUthealth centerMcgovern medical schoolHarris health lyndonb johnson hospital